Evidence map›Paper›PMID 35689866›Full record

ArticleJournal of the neurological sciences2022

Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series.

Marcello Moccia, Antonio Riccardo Buonomo, Riccardo Scotto, Giulio Viceconte, Mariano Nobile, Roberta Lanzillo, Vincenzo Brescia Morra, Ivan Gentile, on the behalf of the Federico II COVID-19 Team

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the neurological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Marcello MocciaMultiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Federico II University, Naples, Italy. Electronic address: marcello.moccia@unina.it.
Antonio Riccardo BuonomoMultiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Federico II University, Naples, Italy; Department of Clinical Medicine and Surgery, Section of Infectious Diseases, Federico II University, Naples, Italy.
Riccardo ScottoDepartment of Clinical Medicine and Surgery, Section of Infectious Diseases, Federico II University, Naples, Italy.
Giulio ViceconteDepartment of Clinical Medicine and Surgery, Section of Infectious Diseases, Federico II University, Naples, Italy.
Mariano NobileDepartment of Clinical Medicine and Surgery, Section of Infectious Diseases, Federico II University, Naples, Italy.
Roberta LanzilloMultiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Federico II University, Naples, Italy.
Vincenzo Brescia MorraMultiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Federico II University, Naples, Italy.
Ivan GentileDepartment of Clinical Medicine and Surgery, Section of Infectious Diseases, Federico II University, Naples, Italy.
on the behalf of the Federico II COVID-19 Team
Federico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).

Indexed as

COVID-19Multiple SclerosisAntibodies, MonoclonalAntibodies, ViralCOVID-19 VaccinesHumansAntibodies, MonoclonalAntibodies, ViralCOVID-19 VaccinesCOVID-19Monoclonal antibodiesMultiple sclerosisTreatment

Identifiers

PMID35689866
PMCPMC9159779
OpenAlexW4281856417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.